SOUTH SAN FRANCISCO --(BUSINESS WIRE)--Aug. 9, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the second quarter ended June 30, 2018 and provided a
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 12, 2018-- Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the comprehensive results of the previously
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 27, 2018-- Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the preclinical results of its oral
Safety and tolerability profile comparable to placebo Primary efficacy endpoint not achieved - Positive trend in two important subgroups SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 4, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 1, 2018-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour , M.D., president and chief executive
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 31, 2018-- Vaxart, Inc. (NASDAQ:VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo , Ph.D., lead scientist of Vaxart , will
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 15, 2018-- Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the first quarter ended March 31,
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Taylor , M.D., as Chief Medical Officer. Dr.
2017 Net Sales of Inavir ® in Japan Exceeded ¥20 Billion, Triggering USD $5 Million Milestone Payment SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 20, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 19, 2018-- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of Brant Biehn as Senior Vice President,
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 16, 2018-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that new preclinical data on its intranasal Chikungunya
SOUTH SAN FRANCISCO, Calif., April 2, 2018 — Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that Wouter Latour , M.D., president and chief executive officer of Vaxart , will
Issued Claims Cover High Yield Production Process of Phase 2 Antiviral SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT) a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will present clinical data from two Phase 1 studies of its
